background preloader

Delveinsight

Facebook Twitter

Delve Insight

A Leading Business Consulting and Market Research Firm to deliver critical information to leading decision makers across the Drug value chain.

13 Quotes of A P J Abdul Kalam in Hindi (ऐ पी जे अब्दुल कलाम के 13 अनमोल विचार) Immune Check Activators- Competitive Landscape, Technology and Pipeline Analysis, 2017. DelveInsight's report deals with the TNFR/TNF superfamily members as agents of Cancer Immunotherapy that have brought a new dawn upon the existing therapies for cancer.

Immune Check Activators- Competitive Landscape, Technology and Pipeline Analysis, 2017

Controlling diverse facets of immune function, it has brought into application a technology that rested in the pipeline for years. In the present scenario, members of the TNFR/TNF superfamily are being targeted to maintain, modulate and regulate body’s own immune system to fight cancer. The rationale of this therapy is to mitigate/ avoid side effects, resistance, toxicity and pain brought by the combination therapy of surgery, radiation and chemotherapy. The future of this therapy lies strong as will be seen before 2020 as majority of its products will show results on safety, efficacy and dosing as they move to their Phase II trials in the provided timeline. Note: This report will be delivered to the client in 1-2 business days. PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017. DelveInsight Report, “PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017” gives the comprehensive insights on the PD-1 and PDl-1 Inhibitors.

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

The report has provided the analysis on the worldwide therapeutic market of PD-1 and PD-L1 inhibitors including information of Marketed molecules, detailed profiling of Pipeline assets and their pathways. The report has covered the therapeutics assessment of pipeline molecules by mechanism of action (MoA), route of administration (RoA), molecule type, along with latest updates. Report is also dealing with detailed epidemiology of all prevalent indications. Report has also covered other Commercial Aspects such as the Current and Future Market, Barriers and challenges, SWOT analysis. The report has also thrown light on the combinations therapies with Immune-check point Inhibitors (PD-1 and PDL-1), provided the information of ongoing collaborations for the development of combinations regimens. Indication Pipeline Insights.

Biotech Competitive Intelligence- Competitor Benchmarking, Product monitoring. Pharma Reports & Updates, Biological strategic Reports.